Formulation And Evaluation Of Bi-Layer Tablets Of Ketoprofen And Omeprazole Using Box-Behnken Design

The present study aims to develop and optimize bi-layer tablets containing Ketoprofen and Omeprazole using the Box-Behnken Design (BBD). Ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), was formulated for sustained release, whereas Omeprazole, a proton pump inhibitor (PPI), was included in the immediate-release layer to counteract gastrointestinal side effects. The Box-Behnken Design was applied to optimize key formulation parameters such as polymer concentration, binder concentration, and filler concentration for the Ketoprofen layer. The Omeprazole layer was optimized for enteric coating using a similar design approach. The bi-layer tablets were prepared by compression using a bilayer tablet press, and their physical, chemical, and in-vitro dissolution characteristics were evaluated. The optimization process allowed for precise control of drug release kinetics, ensuring effective therapeutic outcomes. The final formulation exhibited desirable physical properties, drug release profiles, and stability. The sustained release of Ketoprofen over 12 hours provided prolonged anti-inflammatory action, while the immediate release of Omeprazole within 60 minutes ensured gastric protection. Furthermore, stability studies conducted under accelerated conditions demonstrated that the formulation retained its integrity over time. The application of the Box-Behnken Design facilitated an efficient experimental approach, reducing the number of trials while ensuring optimal formulation development. The study successfully demonstrates the feasibility of formulating a bi-layer tablet that enhances patient compliance by integrating an anti-inflammatory drug with a gastroprotective agent. The optimized formulation offers significant potential in the management of inflammatory disorders while minimizing adverse gastrointestinal effects associated with NSAID therapy. Future studies may focus on in-vivo pharmacokinetic and clinical evaluations to confirm therapeutic efficacy.

Publication Details

Journal
Journal of Carcinogenesis
Published
2025-01-01
DOI
https://doi.org/10.64149/j.carcinog.24.7s.858-865
Primary Topic
Drug Solubulity and Delivery Systems
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Formulation And Evaluation Of Bi-Layer Tablets Of Ketoprofen And Omeprazole Using Box-Behnken Design

Journal of Carcinogenesis
Drug Solubulity and Delivery Systems
article

Formulation And Evaluation Of Bi-Layer Tablets Of Ketoprofen And Omeprazole Using Box-Behnken Design

article en

Abstract

The present study aims to develop and optimize bi-layer tablets containing Ketoprofen and Omeprazole using the Box-Behnken Design (BBD). Ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), was formulated for sustained release, whereas Omeprazole, a proton pump inhibitor (PPI), was included in the immediate-release layer to counteract gastrointestinal side effects. The Box-Behnken Design was applied to optimize key formulation parameters such as polymer concentration, binder concentration, and filler concentration for the Ketoprofen layer. The Omeprazole layer was optimized for enteric coating using a similar design approach. The bi-layer tablets were prepared by compression using a bilayer tablet press, and their physical, chemical, and in-vitro dissolution characteristics were evaluated. The optimization process allowed for precise control of drug release kinetics, ensuring effective therapeutic outcomes. The final formulation exhibited desirable physical properties, drug release profiles, and stability. The sustained release of Ketoprofen over 12 hours provided prolonged anti-inflammatory action, while the immediate release of Omeprazole within 60 minutes ensured gastric protection. Furthermore, stability studies conducted under accelerated conditions demonstrated that the formulation retained its integrity over time. The application of the Box-Behnken Design facilitated an efficient experimental approach, reducing the number of trials while ensuring optimal formulation development. The study successfully demonstrates the feasibility of formulating a bi-layer tablet that enhances patient compliance by integrating an anti-inflammatory drug with a gastroprotective agent. The optimized formulation offers significant potential in the management of inflammatory disorders while minimizing adverse gastrointestinal effects associated with NSAID therapy. Future studies may focus on in-vivo pharmacokinetic and clinical evaluations to confirm therapeutic efficacy.

Journal of Carcinogenesis
Openalex Percentile: Top 79%
Drug Solubulity and Delivery Systems
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.